In this video, InMed’s CEO, Eric A. Adams, explains the neuritogenesis process and how this process is essential for neuronal signaling and healthy brain functioning.
Neuritogenesis is the extension of neurites, which are the branchlike structures extending from a neuron and are essential for cell-to-cell communication in the brain. The neuritogenesis process slows down in adults, and to a greater degree in a brain affected by Alzheimer’s disease. The regrowth of neurites or extension of neurites presents an opportunity to reverse neuronal damage caused by Alzheimer’s disease.
InMed’s INM-901, a drug candidate in preclinical studies, has demonstrated an ability to promote neurite outgrowth, signifying enhanced neuronal function. Preclinical studies of INM-901 also demonstrated neuroprotective effects by reducing cell death in an amyloid-beta-induced cytotoxicity study, reduced neuroinflammation and a trend in improvement in cognitive function and memory, locomotor activity, anxiety-based behavior, sound awareness and neuronal function. These studies of INM-901 were performed using well-characterized Alzheimer’s disease preclinical study models.
